Search research articles

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Lineage Commitment

Lineage Commitment

Commitment is the process whereby stem cells:

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.

Journal for immunotherapy of cancer·2026

Same author

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Prognostic Significance, Predictive Value, and Emerging Directions for Clinical Implementation.

Cancers·2026

Same author

Case Report: durable response to pulsed electric field ablation in combination with immune checkpoint inhibitors in HER2-low breast cancer through activation of interferon signaling.

Frontiers in oncology·2026

Same author

Characterization of Oncogenic and Immunogenic Profiling in Patients with Breast Cancer Tumors After Radiation Therapy.

International journal of molecular sciences·2026

Same author

Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy.

Frontiers in immunology·2026

Same author

The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists.

Cells·2025

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Therapeutic implications of leukemic stem cell pathways.

Saranya Chumsri¹, William Matsui, Angelika M Burger

¹Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|November 17, 2007

Summary

This summary is machine-generated.

Cancer stem cells drive leukemia, regulated by specific genes. Targeting these stemness factors offers therapeutic potential, requiring biomarker integration in clinical trials for effective leukemia treatment.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

Related Experiment Videos

Last Updated: Jul 10, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

Area of Science:

Cancer Biology
Hematology
Stem Cell Research

Background:

Tumors contain a heterogeneous cell mass, including a rare population of cancer stem cells.
Cancer stem cell (CSC) biology is well-exemplified in human myeloid leukemia.
Normal and malignant hematopoietic stem cells share critical stemness genes regulating self-renewal and development.

Purpose of the Study:

To explore the concept of cancer stem cells in leukemia.
To identify therapeutic targets within stemness pathways.
To inform clinical trial design for leukemia stem cell-directed therapies.

Main Methods:

Comparative analysis of stemness gene activation in normal hematopoietic stem cells versus leukemia stem cells.
Review of existing therapeutic strategies and their potential application to leukemia stem cells.
Discussion of clinical trial design modifications and biomarker inclusion.

Main Results:

Stemness factors like Notch and telomerase exhibit differential activation between normal and malignant hematopoietic stem cells.
These differential activations present potential therapeutic vulnerabilities.
Existing leukemia treatments may be adapted to target leukemia stem cells.

Conclusions:

Leukemia stem cells represent a critical target for novel and existing therapies.
Exploiting differences in stemness factor activation can guide therapeutic development.
Clinical translation necessitates revised trial designs incorporating stem cell biomarkers.